Market cap
$8,191 Mln
Recently Viewed
Clear All$44.96
$0.00 (0.00%)As on 01-Aug-2024 09:30EDT
Market cap
$8,191 Mln
Revenue (TTM)
$16 Mln
P/E Ratio
--
P/B Ratio
14.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-100 Mln
ROE
-0.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-12.8
Debt to Equity
0.6
Book Value
$--
EPS
$-2.8
Face value
--
Shares outstanding
182,195,008
CFO
$-1,076.52 Mln
EBITDA
$-1,263.20 Mln
Net Profit
$-1,345.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cerevel Therapeutics Holdings (CERE)
| 6.0 | 10.0 | 5.3 | 47.0 | 22.2 | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Cerevel Therapeutics Holdings (CERE)
| 34.4 | -2.7 | 95.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cerevel Therapeutics Holdings (CERE)
|
45.0 | 8,191.5 | 16.5 | -460.5 | -2,791.7 | -110 | -- | 14.5 |
| 0.6 | 1.7 | 12.0 | -35.0 | -184.0 | -- | -- | 2.1 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b... clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc. Read more
Executive Chairman
Dr. N. Anthony Coles Jr., M.P.H.
Executive Chairman
Dr. N. Anthony Coles Jr., M.P.H.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cerevel Therapeutics Holdings Inc (CERE) is $44.96 (NASDAQ) as of 01-Aug-2024 09:30 EDT. Cerevel Therapeutics Holdings Inc (CERE) has given a return of 22.2% in the last 3 years.
Since, TTM earnings of Cerevel Therapeutics Holdings Inc (CERE) is negative, P/E ratio is not available.
The P/B ratio of Cerevel Therapeutics Holdings Inc (CERE) is 14.51 times as on 13-Aug-2024, a 218 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-15.87
|
10.19
|
|
2022
|
-13.55
|
9.14
|
|
2021
|
-19.97
|
7.67
|
|
2020
|
-8.06
|
3.19
|
|
2019
|
--
|
--
|
The 52-week high and low of Cerevel Therapeutics Holdings Inc (CERE) are Rs -- and Rs -- as of 25-Apr-2026.
Cerevel Therapeutics Holdings Inc (CERE) has a market capitalisation of $ 8,191 Mln as on 13-Aug-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Cerevel Therapeutics Holdings Inc (CERE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.